VivoSeq
Neurology

Neuromuscular Blocking Agents

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Neuromuscular Blocking Agents is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Recruiting1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Management of Neuromuscular Blocking Agents and Their Antagonism
Recruiting·EErasme University Hospital·N/A·NCT06238219·3,000 enrolled
Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery
Not yet recruiting·XXijing Hospital·Phase 3·NCT07271875·560 enrolled
Neuromuscular Blocking Agents in the Elderly
Completed·—·N/A·NCT03857750·32 enrolled
Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Completed·AAssistance Publique Hopitaux De Marseille·Phase 4·NCT00299650·340 enrolled
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
Completed·—·N/A·NCT02914119·30,430 enrolled
Observational Study to Evaluate the Current Neuromuscular Monitoring Practice Used After Different Types of Surgery, for Which Neuromuscular Blocking Agents Were Used, With or Without Blocking Reversal (P06556)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT01213264·659 enrolled
Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients
Completed·UUniversity Hospital, Toulouse·Phase 4·NCT05026125·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)